The Human Phosphatase Interactome

Total Page:16

File Type:pdf, Size:1020Kb

The Human Phosphatase Interactome FEBS Letters 586 (2012) 2732–2739 journal homepage: www.FEBSLetters.org Review The human phosphatase interactome: An intricate family portrait ⇑ Francesca Sacco a,1, Livia Perfetto a,1, Luisa Castagnoli a, Gianni Cesareni a,b, a Department of Biology, University of Rome ‘‘Tor Vergata’’, Rome, Italy b Research Institute ‘‘Fondazione Santa Lucia’’, Rome, Italy article info abstract Article history: The concerted activities of kinases and phosphatases modulate the phosphorylation levels of Received 23 March 2012 proteins, lipids and carbohydrates in eukaryotic cells. Despite considerable effort, we are still miss- Revised 8 May 2012 ing a holistic picture representing, at a proteome level, the functional relationships between Accepted 8 May 2012 kinases, phosphatases and their substrates. Here we focus on phosphatases and we review and inte- Available online 21 May 2012 grate the available information that helps to place the members of the protein phosphatase super- Edited by Marius Sudol, Giulio Superti-Furga families into the human protein interaction network. In addition we show how protein interaction and Wilhelm Just domains and motifs, either covalently linked to the phosphatase domain or in regulatory/adaptor subunits, play a prominent role in substrate selection. Keywords: Ó 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. Human phosphatome Phosphatase family classification Substrate recognition specificity 1. Introduction protein kinases. 428 are known or predicted to phosphorylate ser- ine and threonine residues, while the remaining 90 are members of Phosphorylation is a widespread post-translational modifica- the tyrosine kinase family [3,12]. By contrast, in the human gen- tion governing signal propagation [1]. Indeed phosphorylation is ome there are only approximately 200 phosphatases, targeting an efficient mean to control cell response to internal and external phosphorylated proteins or lipids. cues: it is rapid, taking as little as a few seconds, it does not require Over the past decades, much of the interest of the scientific com- new proteins to be synthesized or degraded and can be easily munity has focused on protein kinases, protein phosphatases being reverted. Protein phosphorylation plays a key role in controlling considered less interesting house-keeping enzymes playing a non- a variety of cellular processes, such as migration, proliferation, specific role in modulating phosphoprotein homeostasis. Recent apoptosis, differentiation, metabolism, organelle trafficking, findings, however, have led to the emerging recognition that pro- immunity, learning and memory [2–4]. Thus, it is not surprising tein phosphatases play key roles in setting the levels of tyrosine, that aberrant phosphorylation profiles correlate with disease serine and threonine phosphorylation in cells, thus participating conditions such as cancer, diabetes and neurodegenerative or in the regulation of many physiological processes, including cell inflammatory disorders [5–7]. Eukaryotic protein phosphorylation growth, tissue differentiation and inter-cellular communication typically occurs on serine, threonine or tyrosine residues. Olsen [5,13,14]. et al. have found the distribution of pSer, pThr, pTyr sites in the Many excellent comprehensive reviews have discussed the human proteome to be around 79.3%, 16.9% and 3.8% respectively different phosphatase superfamilies, their evolution and the mech- [8]. Furthermore approximately 17000 proteins have at least one anisms underlying substrate recognition specificity [13–17,12]. annotated residue in the Phosphosite database [9]. Indeed protein Despite the progress, identification of functional in vivo substrates kinases are one of the largest gene family in eukaryotes, making up remains a challenge. As a consequence, we are still missing a about 2% of the genome [10,11]. The human genome encodes 518 holistic picture representing, at a proteome level, the functional relationships between phosphatases and substrates. In this short contribution, we propose a phosphatase classification and report Abbreviations: PTP, protein tyrosine phosphatase; LP, lipid phosphatase; PPP, a comprehensive analysis of our current understanding and cover- phosphoprotein phosphatases; PPM, metallo-dependent protein phosphatase; HAD, age of the phosphatase interactome. Finally, we discuss how this haloacid dehalogenase; RS, regulatory subunit intricate network of interactions can help to define the function ⇑ Corresponding author. E-mail address: [email protected] (G. Cesareni). of poorly characterized phosphatases and to identify their sub- 1 These authors contributed equally. strates. 0014-5793/$36.00 Ó 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.febslet.2012.05.008 F. Sacco et al. / FEBS Letters 586 (2012) 2732–2739 2733 3 NRPTPs (21) Classical PTPs (41) PTPs (108) 3 RPTPs (20) 2 VH1-like (63) MKPs (12) Atypical DSPs (18) CDC14s (4) PRLs (3) MTMRs (14) PTENs (9) LM-PTP (1) SSHs (3) CDC25C (3) PPPs (13) Phosphatase classification 1 PPMs (15) HADs (11) HADs (21) 2,3 FCPs (6) EYAs (4) LPTs (15) 2 LPs (37) Li-sensitive (7) INPP5 (15) NUDT (5) Fig. 1. Classification of protein phosphatase superfamilies. Protein phosphatases were first classified into six different families according to the catalytic domain InterPro annotation (1). Next each phosphatase family was further subdivided into different classes according to their preferred substrates (2) or literature annotation (3). The number of phosphatases in each family or class is in parenthesis. 2. Phosphatase classification - PPP by the serine/threonine-specific protein phosphatase domain (IPR006186); 2.1. A complete compendium of phosphatase domains - PPM by the Protein phosphatase 2C-like domain (IPR001932); - HAD by the Haloacid dehalogenase-like hydrolase domain A number of reports have discussed in detail the different phos- (IPR005834) or HD domain (IPR023279); phatase superfamilies. Here we aim at a catalogue of all the en- - LP by one of the following three domains: phosphatidic acid zymes removing a phosphate group from proteins or lipids, phosphatase (IPR000326), inositol monophosphatase including their accessory subunits. To obtain such a comprehen- (IPR000760) and inositol polyphosphate-related phosphatase sive list, we first screened the literature and protein databases to (IPR000300); retrieve a list of 250 proteins 194 of which contain a phosphatase - NUDT by the NUDIX hydrolase domain (IPR000086). catalytic domain, while the remaining 56 where classified as regu- latory subunits (RSs). These six main families were further subdivided into classes, Next, to achieve proteome wide coverage of the proteins con- according to different criteria: sequence homology in the catalytic taining phosphatase domains we used a three step procedure: domain, substrate specificity and literature annotation (Fig. 1). The (i) we first recovered from InterPro [18] the sequences of the cat- 211 catalytic domains captured by this procedure were aligned alytic domains and aligned them with the ClustalW2 program with ClustalW2 and the resulting sequence similarity tree is shown [19]; (ii) clustering analysis allowed the classification of the phos- in Fig. 2. This graphic representation should not be interpreted as phatase domains into 13 different subgroups; (iii) each subgroup representing an evolutionary relationship between the different alignment was used for a PSI-BLAST search, against the human phosphatase superfamilies. proteome [20]. Hits with a p-value <0.001 were either retained in the group they were already assigned to, or added as new en- 4. Catalytic specificity and substrate selection tries to our phosphatase compendium. This strategy resulted in a collection of 211 Phosphatase catalytic domains distributed in 199 Phosphatases have been considered promiscuous enzymes, dis- proteins. playing little intrinsic substrate specificity when assayed in vitro. Some published evidence, on the contrary, indicates that they may 3. Phosphatase classification show remarkable preference for specific substrates in vivo. The reac- tion rate for a specific substrate is defined by the Michaelis Menten The 211 phosphatase domains in the compendium were next equation linking the rate of enzymatic reaction to substrate concen- assigned to 6 families defined by catalytic domain sequence simi- tration and to the rate constant kcat. Thus, enzymatic specificity may larity, after taking into account InterPro annotations: be achieved by increasing the ratio of the catalytic activity of the enzyme toward physiological substrates over the ‘‘background’’ - PTP membership is defined by the protein-tyrosine phospha- catalytic activity for similar non-physiological substrates. Such tase domain (IPR016130); intrinsic catalytic specificity can be obtained by shaping the 2734 F. Sacco et al. / FEBS Letters 586 (2012) 2732–2739 P PPP1CA-P62136 9 PPP2CB-P6271 PPP6C-O00743 PPP2CA-P67775 P PPP4C-P6051 P EPM2A-O95278 P CDKN3-Q16667 9 TP 298 0 1 1 STYXL1 2 6 8454 2 C DUSP 0 DUSP3-P51452 J8 M1 C 81 9 Q DUSP26-Q9BV47 P4 64 - 1 - M P 0 6 - A20 P53041 51 DUSP13- C- Q8WUK - 14 2 5 D 3 DUPD1-Q68J44 D 27-Q5VZP5 3 USP22-Q9NRW 6 1-O148 S - DUSP15-Q9H1R2 -Q P3 8 6 Q9Y6 F DUSP19-Q8WTR2 P D1-B0Y P3C 7 E 928 - EF2-O1483 5A B- Q01968 3 Q PP5C - 0 5 5 4 PPP1CB-P62140 PPP3C 8 P PPP3CB-P1 DUSP8-Q1320 PP 0 P -O15056 DUSP16-Q9BY8 6 PP P 0 PP Q B J HAC 5 PPA1-Q1 9UI 8 PPA2-Q9H2U2 5D-Q D 8 INP I INP P 94 DUSP2-Q0592USP5-Q16
Recommended publications
  • Multigene Panels in Prostate Cancer Risk Assessment
    Evidence Report/Technology Assessment Number 209 Multigene Panels in Prostate Cancer Risk Assessment Evidence-Based Practice Evidence Report/Technology Assessment Number 209 Multigene Panels in Prostate Cancer Risk Assessment Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10060-1 Prepared by: McMaster University Evidence-based Practice Center Hamilton, ON, Canada Investigators: Julian Little, Ph.D. Brenda Wilson, M.B.Ch.B., M.Sc., M.R.C.P. (UK), FFPH Ron Carter, Ph.D. Kate Walker, M.Sc.PT. Pasqualina Santaguida, Ph.D. Eva Tomiak, M.D. Joseph Beyene, Ph.D. Parminder Raina, Ph.D. AHRQ Publication No. 12-E020-EF July 2012 This report is based on research conducted by the McMaster University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10060-1). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supp Table 1.Pdf
    Upregulated genes in Hdac8 null cranial neural crest cells fold change Gene Symbol Gene Title 134.39 Stmn4 stathmin-like 4 46.05 Lhx1 LIM homeobox protein 1 31.45 Lect2 leukocyte cell-derived chemotaxin 2 31.09 Zfp108 zinc finger protein 108 27.74 0710007G10Rik RIKEN cDNA 0710007G10 gene 26.31 1700019O17Rik RIKEN cDNA 1700019O17 gene 25.72 Cyb561 Cytochrome b-561 25.35 Tsc22d1 TSC22 domain family, member 1 25.27 4921513I08Rik RIKEN cDNA 4921513I08 gene 24.58 Ofa oncofetal antigen 24.47 B230112I24Rik RIKEN cDNA B230112I24 gene 23.86 Uty ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 22.84 D8Ertd268e DNA segment, Chr 8, ERATO Doi 268, expressed 19.78 Dag1 Dystroglycan 1 19.74 Pkn1 protein kinase N1 18.64 Cts8 cathepsin 8 18.23 1500012D20Rik RIKEN cDNA 1500012D20 gene 18.09 Slc43a2 solute carrier family 43, member 2 17.17 Pcm1 Pericentriolar material 1 17.17 Prg2 proteoglycan 2, bone marrow 17.11 LOC671579 hypothetical protein LOC671579 17.11 Slco1a5 solute carrier organic anion transporter family, member 1a5 17.02 Fbxl7 F-box and leucine-rich repeat protein 7 17.02 Kcns2 K+ voltage-gated channel, subfamily S, 2 16.93 AW493845 Expressed sequence AW493845 16.12 1600014K23Rik RIKEN cDNA 1600014K23 gene 15.71 Cst8 cystatin 8 (cystatin-related epididymal spermatogenic) 15.68 4922502D21Rik RIKEN cDNA 4922502D21 gene 15.32 2810011L19Rik RIKEN cDNA 2810011L19 gene 15.08 Btbd9 BTB (POZ) domain containing 9 14.77 Hoxa11os homeo box A11, opposite strand transcript 14.74 Obp1a odorant binding protein Ia 14.72 ORF28 open reading
    [Show full text]
  • SSH3 Antibody Cat
    SSH3 Antibody Cat. No.: 55-994 SSH3 Antibody SSH3 Antibody immunohistochemistry analysis in formalin Flow cytometric analysis of Hela cells (right histogram) fixed and paraffin embedded human breast carcinoma compared to a negative control cell (left histogram).FITC- followed by peroxidase conjugation of the secondary conjugated goat-anti-rabbit secondary antibodies were antibody and DAB staining. used for the analysis. Confocal immunofluorescent analysis of SSH3 Antibody with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor555 phalloidin (red). DAPI was used to stain the cell nuclear (blue). Specifications October 1, 2021 1 https://www.prosci-inc.com/ssh3-antibody-55-994.html HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This SSH3 antibody is generated from rabbits immunized with a KLH conjugated synthetic IMMUNOGEN: peptide between 575-602 amino acids from the C-terminal region of human SSH3. TESTED APPLICATIONS: Flow, IF, IHC-P, WB For WB starting dilution is: 1:1000 For IHC-P starting dilution is: 1:50~100 APPLICATIONS: For FACS starting dilution is: 1:10~50 For IF starting dilution is: 1:10~50 PREDICTED MOLECULAR 73 kDa WEIGHT: Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • SSH3 Promotes Malignant Progression of HCC by Activating FGF1-Mediated FGF/FGFR Pathway
    European Review for Medical and Pharmacological Sciences 2020; 24: 11561-11568 SSH3 promotes malignant progression of HCC by activating FGF1-mediated FGF/FGFR pathway Q.-S. SHI, Y.-H. ZHANG, J. LONG, Z.-L. QIAN, C.-X. HU Department of Oncology Minimally Invasive Interventional Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, China Abstract. – OBJECTIVE: To investigate the Introduction impact of silencing SSH3 on the expression of FGF/FGFR pathway-related genes FGF1, FG- As the third largest cancer killer in the world, FR1, and FGFR2 in hepatocellular carcinoma the mortality and morbidity of hepatocellular car- (HCC) cell line, so as to further understand the role of SSH3 in proliferation and apoptosis of cinoma (HCC) are increasing year by year around 1,2 HCC cells. the world . In China, it has also become one of PATIENTS AND METHODS: TWe first de- the most common tumors with the highest degree tected SSH3 expression in 51 pairs of tumor of malignancy, and more than 300,000 patients tissue specimens and adjacent tissues collect- die of this cancer every year, which is related to ed from HCC patients through quantitative Re- its biological characteristics of prone to recur- al Time-Polymerase Chain Reaction (qRT-PCR) 3,4 and analyzed the interplay between SSH3 ex- rence and metastasis . The development of HCC pression and clinical characteristics of HCC is a complex process involving multiple genes in patients. In vitro, after SSH3-silenced human vivo and coordinated by multiple steps5,6. At pres- HCC cell line was constructed by lentiviral trans- ent, surgery is one of the most effective methods fection, Cell Counting Kit-8 (CCK-8), cell cloning for HCC treatment, however, the high incidence assay, and flow apoptosis methods were con- of intrahepatic metastasis and vascular invasion ducted to explore the HCC cell functions.
    [Show full text]
  • DNA Methylation Profiling Identifies the HOXA11 Gene As an Early Diagnostic and Prognostic Molecular Marker in Human Lung Adenocarcinoma
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 20), pp: 33100-33109 Research Paper DNA methylation profiling identifies the HOXA11 gene as an early diagnostic and prognostic molecular marker in human lung adenocarcinoma Qun Li1,2,*, Chang Chen3, Xiaohui Ren1, Weihong Sun1,* 1Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200031, China 2The State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China 3Department of Orthodontics, The First Affiliated Hospital of Zhengzhou University, Stomatological College Zhengzhou University, Zhengzhou, 450052, China *These authors contributed equally to this work Correspondence to: Weihong Sun, email: [email protected] Keywords: HOXA11, hypermethylation, lung adenocarcinoma, adenocarcinoma in situ, prognosis Received: October 11, 2016 Accepted: March 14, 2017 Published: March 23, 2017 Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT DNA hypermethylation plays important roles in carcinogenesis by silencing key genes. The goal of our study was to identify pivotal genes using MethyLight and assessed their diagnostic and prognostic values in lung adenocarcinoma (AD). In the present study, we detected DNA methylation at sixteen loci promoter regions in twenty one pairs of primary human lung AD tissues and adjacent non-tumor lung (AdjNL) tissues using the real-time PCR (RT-PCR)-based method MethyLight.
    [Show full text]
  • Genetic Alterations of Protein Tyrosine Phosphatases in Human Cancers
    Oncogene (2015) 34, 3885–3894 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Genetic alterations of protein tyrosine phosphatases in human cancers S Zhao1,2,3, D Sedwick3,4 and Z Wang2,3 Protein tyrosine phosphatases (PTPs) are enzymes that remove phosphate from tyrosine residues in proteins. Recent whole-exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. Beside PTPN11, which functions as an oncogene in leukemia, genetic and functional studies indicate that most of mutant PTPs are tumor suppressor genes. Identification of the substrates and corresponding kinases of the mutant PTPs may provide novel therapeutic targets for cancers harboring these mutant PTPs. Oncogene (2015) 34, 3885–3894; doi:10.1038/onc.2014.326; published online 29 September 2014 INTRODUCTION tyrosine/threonine-specific phosphatases. (4) Class IV PTPs include Protein tyrosine phosphorylation has a critical role in virtually all four Drosophila Eya homologs (Eya1, Eya2, Eya3 and Eya4), which human cellular processes that are involved in oncogenesis.1 can dephosphorylate both tyrosine and serine residues. Protein tyrosine phosphorylation is coordinately regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases 1 THE THREE-DIMENSIONAL STRUCTURE AND CATALYTIC (PTPs). Although PTKs add phosphate to tyrosine residues in MECHANISM OF PTPS proteins, PTPs remove it. Many PTKs are well-documented oncogenes.1 Recent cancer genomic studies provided compelling The three-dimensional structures of the catalytic domains of evidence that many PTPs function as tumor suppressor genes, classical PTPs (RPTPs and non-RPTPs) are extremely well because a majority of PTP mutations that have been identified in conserved.5 Even the catalytic domain structures of the dual- human cancers are loss-of-function mutations.
    [Show full text]
  • Phosphatome Rnai Screen Identifies Eya1 As a Positive Regulator of Hedgehog Signal Transduction
    Phosphatome RNAi Screen Identifies Eya1 as a Positive Regulator of Hedgehog Signal Transduction The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Eisner, Adriana. 2013. Phosphatome RNAi Screen Identifies Eya1 as a Positive Regulator of Hedgehog Signal Transduction. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181213 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Phosphatome RNAi Screen Identifies Eya1 as a Positive Regulator of Hedgehog Signal Transduction A dissertation presented by Adriana Eisner to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Neurobiology Harvard University Cambridge, Massachusetts June 2013 © 2013 Adriana Eisner All rights reserved. Dissertation Advisor: Dr. Rosalind Segal Adriana Eisner Phosphatome RNAi Screen Identifies Eya1 as a Positive Regulator of Hedgehog Signal Transduction Abstract The Hedgehog (Hh) signaling pathway is vital for vertebrate embryogenesis and aberrant activation of the pathway can cause tumorigenesis in humans. In this study, we used a phosphatome RNAi screen for regulators of Hh signaling to identify a member of the Eyes Absent protein family, Eya1, as a positive regulator of Hh signal transduction. Eya1 is both a phosphatase and transcriptional regulator. Eya family members have been implicated in tumor biology, and Eya1 is highly expressed in a particular subtype of medulloblastoma (MB).
    [Show full text]
  • 5R)-5-Hydroxytriptolide (LLDT-8
    www.nature.com/scientificreports OPEN (5R)-5-Hydroxytriptolide (LLDT- 8) induces substantial epigenetic mediated immune response Received: 24 October 2018 Accepted: 16 July 2019 network changes in fbroblast-like Published: xx xx xxxx synoviocytes from rheumatoid arthritis patients Shicheng Guo1, Jia Liu2,3, Ting Jiang2,3, Dungyang Lee4, Rongsheng Wang2,3, Xinpeng Zhou2, Yehua Jin2, Yi Shen2,3, Yan Wang3, Fengmin Bai2,3, Qin Ding2,3, Grace Wang5, Jianyong Zhang6, Xiaodong Zhou7, Steven J. Schrodi1,8 & Dongyi He2,3 Tripterygium is a traditional Chinese medicine that has widely been used in the treatment of rheumatic disease. (5R)-5-hydroxytriptolide (LLDT-8) is an extracted compound from Tripterygium, which has been shown to have lower cytotoxicity and relatively higher immunosuppressive activity when compared to Tripterygium. However, our understanding of LLDT-8-induced epigenomic impact and overall regulatory changes in key cell types remains limited. Doing so will provide critically important mechanistic information about how LLDT-8 wields its immunosuppressive activity. The purpose of this study was to assess the efects of LLDT-8 on transcriptome including mRNAs and long non-coding RNA (lncRNAs) in rheumatoid arthritis (RA) fbroblast-like synoviocytes (FLS) by a custom genome-wide microarray assay. Signifcant diferential expressed genes were validated by QPCR. Our work shows that 394 genes (281 down- and 113 up-regulated) were signifcantly diferentially expressed in FLS responding to the treatment of LLDT-8. KEGG pathway analysis showed 20 pathways were signifcantly enriched and the most signifcantly enriched pathways were relevant to Immune reaction, including cytokine- cytokine receptor interaction (P = 4.61 × 10−13), chemokine signaling pathway (P = 1.01 × 10−5) and TNF signaling pathway (P = 2.79 × 10−4).
    [Show full text]
  • Comprehensive Protein Tyrosine Phosphatase Mrna Profiling Identifies New Regulators in the Progression of Glioma Annika M
    Bourgonje et al. Acta Neuropathologica Communications (2016) 4:96 DOI 10.1186/s40478-016-0372-x RESEARCH Open Access Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma Annika M. Bourgonje1, Kiek Verrijp2, Jan T. G. Schepens1, Anna C. Navis2, Jolanda A. F. Piepers1, Chantal B. C. Palmen1, Monique van den Eijnden4, Rob Hooft van Huijsduijnen4, Pieter Wesseling2,3, William P. J. Leenders2 and Wiljan J. A. J. Hendriks1* Abstract The infiltrative behavior of diffuse gliomas severely reduces therapeutic potential of surgical resection and radiotherapy, and urges for the identification of new drug-targets affecting glioma growth and migration. To address the potential role of protein tyrosine phosphatases (PTPs), we performed mRNA expression profiling for 91 of the 109 known human PTP genes on a series of clinical diffuse glioma samples of different grades and compared our findings with in silico knowledge from REMBRANDT and TCGA databases. Overall PTP family expression levels appeared independent of characteristic genetic aberrations associated with lower grade or high grade gliomas. Notably, seven PTP genes (DUSP26, MTMR4, PTEN, PTPRM, PTPRN2, PTPRT and PTPRZ1) were differentially expressed between grade II-III gliomas and (grade IV) glioblastomas. For DUSP26, PTEN, PTPRM and PTPRT, lower expression levels correlated with poor prognosis, and overexpression of DUSP26 or PTPRT in E98 glioblastoma cells reduced tumorigenicity. Our study represents the first in-depth analysis of PTP family expression in diffuse glioma subtypes and warrants further investigations into PTP-dependent signaling events as new entry points for improved therapy. Keywords: Glioblastoma, Astrocytoma, EGFR, Oligodendroglioma, IDH1, DUSP26, MTMR4, PTEN, PTP, PTPRM, PTPRN2, PTPRT, PTPRZ1, Malignancy Introduction has slightly improved over the past decades, the prospect Gliomas arise from glial (precursor) cells and represent with current treatment is only a median 15 months fol- the most frequent type of primary brain tumor.
    [Show full text]